Sanuwave Health Stock Price, News & Analysis

SANUWAVE Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced it will host a conference call on November 8, 2024, at 8:30 AM (ET) to discuss its Q3 2024 financial results. Participants can join via toll-free number 1-800-267-6316 or international number 1-203-518-9783 using Conference ID: SANUWAVE. Materials will be available on the company's website, and a replay will be accessible through November 29, 2024, using replay access ID: 11157276.

SANUWAVE Health announced a 1-for-375 reverse stock split effective from October 18, 2024. The common stock will trade on a split-adjusted basis under the symbol SNWV on the OTCQB, with a new CUSIP number, 80303D 305. This move will reduce the outstanding shares from approximately 1.18 billion to 3.15 million. Proportional adjustments will be made to equity awards, convertible notes, and warrants. No fractional shares will be issued; instead, fractional shares will be settled in cash. The reverse stock split will not change the total number of authorized shares or alter any stockholder's percentage interest in the company, except for adjustments due to fractional shares. Stockholders will receive transaction statements and information from the Securities Transfer regarding the exchange process.

SANUWAVE Health (OTCQB: SNWV) reported record quarterly revenues for Q2 FY2024. Key highlights include:

- Q2 2024 revenues of $7.2 million, up 53% year-over-year
- Gross margin of 73%, slightly down from 74% in Q2 2023
- GAAP Operating Income of $2.0 million
- Net income of $6.6 million, compared to a net loss of $7.3 million in Q2 2023
- Adjusted EBITDA of $1.5 million, up from $171,000 in Q2 2023
- 72 UltraMist® systems sold, up from 49 in Q2 2023
- UltraMist® consumables revenue increased by 67% to $4.7 million

The company provided guidance for Q3 2024, expecting revenue growth of 65-75% compared to Q3 2023. SANUWAVE also secured approval for a reverse stock split and 100% participation in its note and warrant exchange offer.

SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of FDA-approved wound care products, has announced a live conference call scheduled for August 13, 2024, at 8:30 AM (ET) to present their Q2 2024 financial results. Investors can access the call via toll-free (1-800-579-2543) or international (1-785-424-1789) numbers using the Conference ID: SANUWAVE. Alternatively, instant telephone access is available through a provided link.

Conference materials will be accessible on the company's website. A replay of the call will be available until September 3, 2024, using specific replay access numbers and ID. This event provides an opportunity for stakeholders to gain insights into SANUWAVE's recent financial performance and future outlook.